South Korea
· Delayed Price · Currency is KRW ST Pharm Statistics
Total Valuation
ST Pharm has a market cap or net worth of KRW 1.57 trillion. The enterprise value is 1.57 trillion.
| Market Cap | 1.57T |
| Enterprise Value | 1.57T |
Important Dates
The next estimated earnings date is Friday, July 25, 2025.
| Earnings Date | Jul 25, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
ST Pharm has 20.15 million shares outstanding. The number of shares has increased by 5.53% in one year.
| Current Share Class | 20.15M |
| Shares Outstanding | 20.15M |
| Shares Change (YoY) | +5.53% |
| Shares Change (QoQ) | +0.07% |
| Owned by Insiders (%) | 7.81% |
| Owned by Institutions (%) | 11.39% |
| Float | 12.39M |
Valuation Ratios
The trailing PE ratio is 52.40 and the forward PE ratio is 38.41. ST Pharm's PEG ratio is 1.28.
| PE Ratio | 52.40 |
| Forward PE | 38.41 |
| PS Ratio | 5.73 |
| PB Ratio | 3.18 |
| P/TBV Ratio | 3.29 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 17.57 |
| PEG Ratio | 1.28 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 29.78, with an EV/FCF ratio of -1,169.20.
| EV / Earnings | 53.20 |
| EV / Sales | 5.72 |
| EV / EBITDA | 29.78 |
| EV / EBIT | 59.06 |
| EV / FCF | -1,169.20 |
Financial Position
The company has a current ratio of 2.08, with a Debt / Equity ratio of 0.24.
| Current Ratio | 2.08 |
| Quick Ratio | 1.08 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | 2.23 |
| Debt / FCF | -88.04 |
| Interest Coverage | 3.47 |
Financial Efficiency
Return on equity (ROE) is 6.27% and return on invested capital (ROIC) is 2.82%.
| Return on Equity (ROE) | 6.27% |
| Return on Assets (ROA) | 2.37% |
| Return on Invested Capital (ROIC) | 2.82% |
| Return on Capital Employed (ROCE) | 4.63% |
| Revenue Per Employee | 419.01M |
| Profits Per Employee | 45.07M |
| Employee Count | 655 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 1.29 |
Taxes
In the past 12 months, ST Pharm has paid 9.05 billion in taxes.
| Income Tax | 9.05B |
| Effective Tax Rate | 24.59% |
Stock Price Statistics
The stock price has decreased by -16.25% in the last 52 weeks. The beta is 0.77, so ST Pharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.77 |
| 52-Week Price Change | -16.25% |
| 50-Day Moving Average | 76,538.00 |
| 200-Day Moving Average | 87,482.00 |
| Relative Strength Index (RSI) | 47.00 |
| Average Volume (20 Days) | 96,278 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ST Pharm had revenue of KRW 274.45 billion and earned 29.52 billion in profits. Earnings per share was 1,488.44.
| Revenue | 274.45B |
| Gross Profit | 93.73B |
| Operating Income | 26.84B |
| Pretax Income | 36.80B |
| Net Income | 29.52B |
| EBITDA | 52.99B |
| EBIT | 26.84B |
| Earnings Per Share (EPS) | 1,488.44 |
Balance Sheet
The company has 119.17 billion in cash and 118.26 billion in debt, giving a net cash position of 910.66 million or 45.19 per share.
| Cash & Cash Equivalents | 119.17B |
| Total Debt | 118.26B |
| Net Cash | 910.66M |
| Net Cash Per Share | 45.19 |
| Equity (Book Value) | 494.30B |
| Book Value Per Share | 24,547.68 |
| Working Capital | 174.59B |
Cash Flow
In the last 12 months, operating cash flow was 89.49 billion and capital expenditures -90.83 billion, giving a free cash flow of -1.34 billion.
| Operating Cash Flow | 89.49B |
| Capital Expenditures | -90.83B |
| Free Cash Flow | -1.34B |
| FCF Per Share | -66.66 |
Margins
Gross margin is 34.15%, with operating and profit margins of 9.78% and 10.76%.
| Gross Margin | 34.15% |
| Operating Margin | 9.78% |
| Pretax Margin | 13.41% |
| Profit Margin | 10.76% |
| EBITDA Margin | 19.31% |
| EBIT Margin | 9.78% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 500.00, which amounts to a dividend yield of 0.64%.
| Dividend Per Share | 500.00 |
| Dividend Yield | 0.64% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 31.86% |
| Buyback Yield | -5.53% |
| Shareholder Yield | -4.90% |
| Earnings Yield | 1.88% |
| FCF Yield | -0.09% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ST Pharm has an Altman Z-Score of 5.41 and a Piotroski F-Score of 5.
| Altman Z-Score | 5.41 |
| Piotroski F-Score | 5 |